In this international, multicenter, single-arm phase 2 trial, tovorafenib monotherapy resulted in clinically meaningful, rapid and durable tumor responses in children and young adults with BRAF-altered relapsed/refractory pLGG. Here, BRAF is linked to neoplasm.